GreenMark Biomedical Inc. has received notice that its project titled "Targeted Remineralization Treatment Using Mineral Loaded Starch Nanoparticles" has been selected for continued funding through the Interdisciplinary Translational Project (ITP) program administered by the Translational Resource Center (TRC). The funding period is expected to run from July 1, 2025, through February 28, 2026, and will provide up to $162,000 in support.
The project aims to explore new delivery formats for regenerative treatments targeting early-stage dental decay. The initiative involves collaboration with dental research teams from the University of Michigan, University of Pittsburgh, and the Wyss Institute at Harvard. GreenMark has been engaged with the TRC since 2018, during which time the center has offered guidance and access to academic, regulatory, and clinical resources related to regenerative medicine development. The TRC also maintains partnerships with institutions including the University of Southern California, multiple University of California campuses, and Stanford University.
According to David H. Kohn, MSE, PhD, Director of the Translational Resource Center, and Natalie C. Roberts, endowed Professor at the University of Michigan Department of Biomedical Engineering and Department of Biologic and Materials Sciences, School of Dentistry, of 109 applications reviewed since 2018, 22 ITP projects have been funded, 14 exited, and eight remain. “GreenMark has been a top performer on its project milestones, being the first to launch a commercial product resulting from our center,” they commented.
“We designed submicron particles capable of being targeted to sites where needed and to break down by natural enzymes in saliva, thereby releasing bioavailable calcium and phosphate, to fill porosities in enamel and occlude exposed dentinal tubules with in-situ generated apatite crystals,” explains co-inventor Nathan Jones, MSc, PhD, VP Technology for GreenMark and Co-Principal Investigator (PI) on the award. Independent third-party testing has shown the tiny mineral-loaded particles can be used to combat dental sensitivity and noninvasively restore early-stage enamel caries lesions.
“This funding is supporting the further development of different product forms beyond our CrystLCare™ Biorestorative dissolvable dental strips, including toothpaste tablets, chewing gums, and edible formulations,” states Co-PI and GreenMark’s Chairman and CEO, Dr. Steven Bloembergen, PhD.
Generating solutions in minimally invasive dentistry, GreenMark Biomedical is committed to transforming dental care through scientific and technological innovation by developing a systems approach for treatment of dental sensitivity and management of caries. The company develops methods to identify, better assess, and monitor caries disease in its earliest stages.
Figures and Images
CrystLCare™ Biorestorative
